Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:
-
Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat
- Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET
- Moderator: Paul Matteis, Head of Therapeutics Research
- Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder (GAD), including key clinical takeaways and implications for the program, as well as expectations for the upcoming Phase 3 Panorama topline results, the second pivotal study of DT120 ODT in GAD.
-
Webcast Link: Please contact your Stifel representative for access to the fireside chat
-
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
- Presentation Date and Time: Wednesday, September 23, 2026 at 9:30 AM ET
- Location: Virtual
-
Webcast Link: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
-
2026 Leerink Partners Biopharma Summit
- Dates: Wednesday, September 23 - Friday, September 25, 2026
- Location: Healdsburg, CA
Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.
About Definium Therapeutics
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX
For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.
Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com
Media Contact:
media@definiumtx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260826612661/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States